Wells Fargo analyst Mohit Bansal raised the firm’s price target on Eli Lilly to $700 from $650 and keeps an Overweight rating on the shares. Consensus 2024 revenues of $39.1B/adjusted EPS of $12.34 look achievable to the firm, but Lilly may guide conservative consistent with 2023. If this is the case, Wells wouldn’t overly read into it and could see buying on weakness.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Zealand Pharma believes it can compete in weight-loss drug market, FT says
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Eli Lilly price target raised to $680 from $630 at Barclays
- New production lapses found at Eli Lilly plant, Reuters reports
- Novo Nordisk, Eli Lilly, others raise prices of hundreds of drugs, WSJ reports